CK0802 for Treatment-Resistant Graft vs. Host Disease
Part of Immune system & allergy clinical trials.
This trial tests a new medicine called CK0802 for patients whose graft versus host disease (a complication after bone marrow transplant) did not improve with standard steroid treatment. The goal is to see if CK0802 can help control this condition when steroids alone haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old (first 3 enrolled must be 18+)
- You have grade 2–4 acute GVHD that hasn't responded to high-dose steroids
- You have not received any other treatment for your acute GVHD before this trial
- You do not have HIV or an uncontrolled infection
- If female and able to become pregnant, you must have a negative pregnancy test
- You are willing to attend all study visits and follow-up appointments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests a new immune cell treatment for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard medications like ruxolitinib. The goal is to see if these special cells can calm the immune attack and help manage symptoms.
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Steroid Refractory Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.